The Fourth Annual Meeting of the European Vascular Genomics Network (EVGN, www.evgn.org), Network of excellence on cardiovascular disease, opened yesterday, September 17th, in the prestigious venue of the University of Bristol (UK), that made available to the event two historical buildings: the Wills Memorial Building, inaugurated by King George V and Queen Mary, and the Merchant Venturers Building.
Run jointly with the European Vascular Biology Organization (EVBO) and the British Atherosclerosis Society and articulated over a three day period (September 17-20), the EVGN Meeting will take place in parallel with the 4th European Meeting on Vascular Biology and Medicine (EMVBM), gathering more than 400 scientists from all over Europe with representatives from the rest of the world. Cardiologists and diabetes researchers, as well as hematologists, thrombosis scientists, gene therapists and oncologists will alternate their presentations to show new data and debate perspectives on the therapeutic side.
“Once again as we did in 2005 – said the President of EVBO Professor Andrew Newby – the simultaneous presence of renowned scientists with different expertise and competence is a unique chance to confront news and views on controversial aspects of vascular disease, an elusive but deadly disease, and to enhance the productivity and the competitiveness of the European scientific community at large”.
The agenda is more than full: 10 plenary speakers, a selection of 45 oral presentations and almost 200 posters complete a rich and comprehensive programme. And tomorrow, Sept. 19, the Young Investigator Award will be assigned to a young distinguished researcher, with the aim of encouraging his/her investigations in years to come.
The opening Hugh Sinclair lecture that concluded the first day of the Meeting was presented by Professor Goran K. Hansson, from the Karolinska Hospital, Center for Molecular Medicine, who offered an elegant state-of-the-art summary of atherosclerosis, with an eye to the most appealing therapeutic perspective: a vaccine against this immune disease. “The current knowledge of atherosclerosis has markedly changed over the latest years” said Hansson, who is a leading scientists in the immunology field. “Today we know that atherosclerosis is an inflammatory disease with both a systemic association and a genetic involvement. Inside the plaques there is a strong immune activity, and day after day we learn more and more about the immunopathogenetic mechanisms with the aid of mouse models that mimic the disease in humans. But we are still a few steps away from a human trial”. There are three unresolved issues. We need: to find the proper antigen for immunization (a good candidate is the LDL particle, Low Density Lipoprotein or bad cholesterol); to clarify the mechanism of action (it has to be decided whether the vaccine wants to reduce bad circulating lipoproteins or act upon immune cells that create inflammation in the artery); finally, we have to identify the optimal administration route. “When we overcome these bottlenecks, we will get to the vaccine.”
Today, September 18th, the EVGN scientists will address some of the most critical topics for cardiovascular disease:
• strategies to modulate angiogenesis (the growth of blood vessels which is necessary to avoid tissue necrosis after ischemia);
• ways to target atherosclerotic plaques;
• the clinical experience in the acute myocardial infarction
“Most of the convened scientists – commented Professor Newby – are at the fore front of the research. We expect interesting news from this fourth EVGN Meeting. We also want to start proceeding on new therapeutic avenues, to improve scientists’ interactions and encourage young talents”.
The European Vascular Genomics Network (EVGN) is the first Network of Excellence on cardiovascular disease funded by the European Commission under the 6th Framework Programme "Life sciences, genomics and biotechnology for health" (Contract Number: LSHM-CT-2003-503254).
The conference is supported by an unrestricted educational grant from Laboratoires SERVIER.
One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center
The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
23.06.2017 | Physics and Astronomy
23.06.2017 | Physics and Astronomy
23.06.2017 | Information Technology